Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

By sparking the immune system into action, radiation therapy makes certain tumors that resist immunotherapy susceptible to ...

During a live event, Bruna Pellini, MD, discussed IO monotherapy as a first-line option for non–small cell lung cancer with ...

During a live event, Mark Yarchoan, MD, and participants discussed their impressions of the CheckMate-9DW trial data in ...

The National Cancer Center Research Institute in Tokyo reports that a newly isolated gut bacterium, designated ...

By sparking the immune system into action, radiation therapy makes certain tumors that resist immunotherapy susceptible to ...

Researchers pinpoint what happens on a cellular and molecular level over time when the cancer is treated with either ...

Dr. Ma discussed key findings that have been shared so far this year on the topic of evolving treatment strategies for ...

A new pilot clinical study will explore the safety and effectiveness of 2 anti-canine monoclonal antibodies on solid tumors ...

Market OverviewThe global Cancer Immunotherapy Market is valued at USD 121.4 Billion in 2024 and is projected to reach a ...